HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (Nasdaq:ARDM) (the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, Pulmaquin®, for treatment of non-cystic fibrosis bronchiectasis (non-CF BE) patients with chronic lung infections with Pseudomonas aeruginosa. Aradigm is currently in Phase 3 clinical trials for this indication.
Help employers find you! Check out all the jobs and post your resume.
